Four new patents open new doors to innovative and precise oral delivery of cannabinoids in the US and Canadian markets. The patents granted to NordicCan cover novel gum base formulations improving oral delivery of cannabinoids.
The worldwide interest in cannabinoids for wellness and medical purposes is growing, and with four new patents, NordicCan is strongly positioned to deliver user-friendly delivery formats to customers in USA and Canada.
“The new patents add to our robust IP portfolio around cannabinoids and will allow our customers to create and offer unique delivery formats to consumers. With our bespoke gum formulations, we have found the key to delivering cannabinoids effectively through gum, which is a consumer appealing format in the North American markets”, says Julie Malbaek, CEO, NordicCan.
As a full Contract Development and Manufacturing Organization, NordicCan follows worldwide regulation and market trends within cannabinoids closely.
“With the increasing acceptance of CBD products for a variety of ailments, the use of cannabinoids is broadening from a niche to a more general health and wellness segment. This also means that we see new consumer groups that are more likely to become CBD users via well-known, controlled unit-dose formats like gums, lozenges or sublingual tablets. With our new patents in place, we are well positioned to support our customers with market relevant formats”, says Julie Malbaek.
The new patents add to the more than 180 patents owned by the Fertin Group, covering the extensive portfolio of consumer friendly delivery formats for active ingredients such as nicotine, cannabinoids and a range of dietary supplements.
For further information, please contact
Julie Malbaek, CEO – NordicCan A/S, JULM@fertin.com
Jesper Neergaard, Senior Principal, Head of IPR at Fertin Pharma and NordicCan, JNR@fertin.com
